RVTY on NYSE
Revvity Inc.
Logo: Revvity, Inc., Public domain, via Wikimedia Commons4
American biotechnology company
Revvity, Inc. is a multinational company headquartered in Waltham, Massachusetts, USA, in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Bio-Rad Laboratories, Waters Corporation or Bruker, or pick any stock.
- TickerRVTY on NYSE1
- Industrybiotechnology1
- HeadquartersWaltham1
- Websiterevvity.com
- Incorporated inMA5
- Business address77 4Th Avenue, Waltham, Ma 024515
- Filer categoryLarge accelerated filer5
See how the biggest companies compare on our leaderboards
Revvity, Inc. is a multinational company headquartered in Waltham, Massachusetts, USA, in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 84% of the revenue Revvity Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product | $2.4B | $2.3B | $2.4B |
| Service | $334.7M | $416.8M | $466.1M |
Business segments
Life Sciences brought in 50% of the revenue Revvity Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Life Sciences | $1.5B | $1.4B | $1.4B |
| Diagnostics | $1.3B | $1.4B | $1.4B |
Regions
Americas brought in 27% of the revenue Revvity Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| Americas | $1.2B | $1.2B | $1.3B |
| Other International | $859.9M | $931.7M | $1.0B |
| Europe | $747.0M | $742.6M | $825.0M |
| Asia | $787.9M | $789.3M | $775.1M |
| China | $454.4M | $450.0M | $425.1M |
| Germany | $193.2M | $162.6M | $177.7M |
| United Kingdom | $125.4M | $112.9M | $126.8M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development8¢$215.8M
- Selling, general and admin35¢$991.9M
- Other costs48¢$1.4B
- Income tax1¢$28.4M
- Profit8¢$241.2M
Out of $2.9B in revenue.7
Where each dollar of operating cash went, fiscal 2025
- Capital spending8¢$73.5M
- Dividends paid4¢$32.8M
- Share buybacks89¢$820.8M
Out of $582.9M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.7
Financial statements
Every line of the income statement in the latest annual report, as filed.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Interest income | -$31.1M | -$73.2M | -$72.1M |
| Change in fair value of investments | $11.5M | -$8.0M | $33.9M |
| Other components of net periodic pension cost (credit) | $871.0K | $8.5M | $19.0M |
| Foreign exchange losses and other expense (income), net | $14.9M | $7.0M | $38.0M |
| Total interest and other expense, net | $88.4M | $30.6M | $117.6M |
| Interest Expense, Nonoperating | $92.2M | $96.3M | $98.8M |
Every line of the balance sheet in the latest annual report, as filed.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $919.9M | $1.2B | $913.2M |
| Accounts receivable, net | $744.7M | $632.4M | |
| Inventories | $379.5M | $367.6M | |
| Other current assets | $195.7M | $186.2M | |
| Total current assets | $2.2B | $2.3B | |
| Property, plant and equipment, net | $479.2M | $482.2M | |
| Operating Lease, Right-of-Use Asset | $165.4M | $167.7M | |
| Intangible assets, net | $2.3B | $2.6B | |
| Beginning balance | $6.6B | $6.5B | $6.5B |
| Other assets, net | $323.5M | $288.4M | |
| Total assets | $12.2B | $12.4B | |
| Current portion of long-term debt | $588.8M | $242.0K | |
| Accounts payable | $185.5M | $167.5M | |
| Accrued expenses and other current liabilities | $557.0M | $485.4M | |
| Total current liabilities | $1.3B | $653.1M | |
| Long-term debt | $2.6B | $3.2B | |
| Long-term liabilities | $807.5M | $770.5M | |
| Operating Lease, Liability, Noncurrent | $148.1M | $151.5M | |
| Total liabilities | $4.9B | $4.7B | |
| Preferred stock$1 par value per share, authorized 1,000,000 shares; none issued or outstanding | $0 | $0 | |
| Common stock$1 par value per share, authorized 300,000,000 shares; issued and outstanding 112,281,000 and 120,646,000 shares at December 28, 2025 and December 29, 2024, respectively | $112.3M | $120.6M | |
| Capital in excess of par value | $1.3B | $2.1B | |
| Retained earnings | $6.1B | $5.8B | |
| Accumulated other comprehensive loss | -$222.1M | -$396.1M | -$276.7M |
| Total stockholders' equity | $7.3B | $7.7B | $7.9B |
| Total liabilities and stockholders' equity | $12.2B | $12.4B | |
| Preferred stock, par value | $1.00 | $1.00 | |
| Preferred stock, authorized | 1.0M shares | 1.0M shares | |
| Preferred stock, issued | 0 shares | 0 shares | |
| Preferred stock, outstanding | 0 shares | 0 shares | |
| Common stock, par value | $1.00 | $1.00 | |
| Common stock, authorized | 300.0M shares | 300.0M shares | |
| Common stock, issued | 112.3M shares | 120.6M shares | |
| Common stock, outstanding | 112.3M shares | 120.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $241.2M | $270.4M | $693.1M |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | -$1.3M | $12.7M | -$513.6M |
| Income from continuing operations | $239.9M | $283.1M | $179.5M |
| Restructuring Charges and Changes in Estimates | $55.9M | $17.5M | $26.6M |
| Depreciation and amortization | $405.3M | $427.8M | $431.8M |
| Stock-based compensation | $22.8M | $37.8M | $41.4M |
| Pension and other post-retirement expense | $3.6M | $9.4M | $23.1M |
| Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) | -$1.4M | -$1.9M | $4.2M |
| Deferred taxes | -$61.5M | -$102.2M | -$123.7M |
| Contingencies and Non-Cash Tax Matters | -$86.0K | -$8.1M | $26.2M |
| Amortization of deferred debt issuance costs, interest rate hedge and accretion of discounts | $4.6M | $6.1M | $7.3M |
| Asset Impairment Charges | $4.8M | $22.8M | $0 |
| Change in fair value of investments | $11.5M | -$8.0M | $33.9M |
| Gain (Loss) on Extinguishment of Debt | $0 | $0 | -$3.7M |
| Unrealized Gain (Loss), Foreign Currency Transaction, before Tax | $273.0K | -$1.1M | $24.1M |
| Accounts receivable, net | -$101.0M | -$16.0M | -$9.0M |
| Inventories, net | $14.8M | $45.1M | -$14.1M |
| Accounts payable | $7.3M | -$26.0M | -$76.4M |
| Accrued expenses and other | -$17.9M | -$21.4M | -$291.8M |
| Net cash provided by operating activities of continuing operations | $589.0M | $665.0M | $279.4M |
| Net cash used in operating activities of discontinued operations | -$6.0M | -$36.7M | -$188.1M |
| Net cash provided by operating activities | $582.9M | $628.3M | $91.3M |
| Capital expenditures | -$73.5M | -$86.6M | -$81.4M |
| Purchases of investments and notes receivables | -$385.0K | -$6.6M | -$6.3M |
| Payments to Acquire Marketable Securities | $0 | $0 | -$1.2B |
| Proceeds from Sale and Maturity of Marketable Securities | $0 | $710.0M | $550.0M |
| Proceeds from Divestiture of Businesses | $304.0K | $2.5M | $153.0K |
| Cash paid for acquisitions, net of cash acquired | $0 | $0 | -$2.1M |
| Net cash (used in) provided by investing activities of continuing operations | -$73.6M | $619.3M | -$761.2M |
| Net cash provided by investing activities of discontinued operations | $56.2M | $156.9M | $2.1B |
| Net cash (used in) provided by investing activities | -$17.4M | $776.2M | $1.3B |
| Payments of Senior Debt | $0 | -$711.5M | -$523.8M |
| Payments of debt financing and equity issuance costs | -$2.5M | $0 | -$15.0K |
| Proceeds from (Repayments of) Other Debt | -$521.0K | -$11.6M | $6.3M |
| Payments for acquisition-related contingent consideration | -$3.8M | -$8.8M | -$10.1M |
| Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised | $2.9M | $7.7M | $4.3M |
| Purchases of common stock | -$820.8M | -$369.6M | -$388.9M |
| Dividends paid | -$32.8M | -$34.5M | -$35.0M |
| Net cash (used in) provided by financing activities | -$857.5M | -$1.1B | -$947.1M |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $48.5M | -$26.1M | -$14.0M |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -$243.4M | $250.1M | $443.6M |
| Interest Paid, Excluding Capitalized Interest, Operating Activity | $86.2M | $91.1M | $94.0M |
| Income taxes | $154.9M | $359.8M | |
| Consideration receivable from sale of Business | $0 | $0 | $241.4M |
Leadership
Who has led Revvity Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
- Chief executive officerRobert F. Friel Jan 29, 2009 to Feb 14, 201915
- Chief executive officerGregory L. Summe Oct 24, 2003 to Sep 5, 200716
- ChairRobert F. Friel Dec 17, 2009 to Feb 14, 201917
- ChairGregory L. Summe Oct 24, 2003 to Mar 3, 200916
- PresidentPrahlad R. Singh Feb 19, 2019 to Apr 10, 201918
- PresidentJames Corbett Feb 6, 2012 to Feb 10, 201219
- PresidentRobert F. Friel Jan 25, 2008 to Oct 2, 201820
- PresidentGregory L. Summe Feb 2, 2006 to Mar 15, 200721
- Chief financial officerFrank Anders Wilson May 19, 2009 to Feb 4, 201522
- Chief financial officerJeffrey D. Capello Feb 2, 2006 to Jan 31, 200823
- Chief financial officerRobert F. Friel Oct 24, 2003 to Nov 1, 200524
- Chief operating officerPrahlad R. Singh Feb 19, 2019 to Apr 10, 201918
- Chief operating officerRobert F. Friel Jan 25, 2008 to Jan 31, 200820
- Chief operating officerJohn Patrick Murphy Aug 2, 2005 to Aug 2, 200525
Board members and other officers (47)
- OfficerAnita Gonzales Jun 16, 2023 to now26
- OfficerMaxwell Krakowiak Sep 6, 2022 to now27
- OfficerMiriame Victor Jan 5, 2021 to now28
- OfficerTajinder Vohra Feb 1, 2018 to now29
- OfficerJames M. Mock May 1, 2018 to Jun 27, 202230
- OfficerDaniel R. Tereau Feb 5, 2016 to Feb 7, 202431
- OfficerDeborah A. Butters Jul 11, 2016 to Feb 10, 202032
- OfficerPrahlad R. Singh Oct 3, 2016 to now33
- OfficerFrank Anders Wilson Feb 10, 2015 to Mar 6, 201834
- OfficerJonathan Divincenzo Dec 3, 2013 to Feb 10, 201635
- OfficerE. Kevin Hrusovsky Feb 6, 2012 to Jun 3, 201336
- OfficerMaurice H. Tenney Feb 6, 2012 to Nov 10, 201437
- OfficerJames Corbett Feb 9, 2012 to May 2, 201938
- OfficerJoel S. Goldberg Feb 9, 2012 to now39
- VP & Chief Accounting OfficerAndrew Okun May 2, 2011 to Apr 14, 202340
- Senior Vice President, HRJohn R. Letcher Feb 5, 2010 to Jun 9, 201541
- VP AND CSODaniel R. Marshak Apr 23, 2008 to Sep 29, 201442
- SVP, Gen. Counsel, & SecretaryKatherine A. Ohara Mar 15, 2007 to Jan 31, 200843
- Vice chairRobert F. Friel Feb 2, 2006 to Jan 31, 200844
- VP & Chief Accounting OfficerMichael Louis Battles Nov 2, 2006 to Feb 3, 200945
- Vice PresidentJohn A. Roush Nov 12, 2004 to Feb 11, 201046
- Chief Accounting OfficerJeffrey D. Capello Oct 24, 2003 to Nov 2, 200547
- Sr. Vice PresidentJohn Patrick Murphy Oct 24, 2003 to Aug 2, 200548
- Sr. Vice PresidentPeter B. Coggins Oct 24, 2003 to Nov 1, 200549
- Senior Vice PresidentRichard F. Walsh Oct 24, 2003 to Jan 28, 201050
- Sr. Vice PresidentRobert A. Barrett Oct 24, 2003 to Mar 5, 200451
- Board memberMichael A. Klobuchar Feb 1, 2024 to now52
- Board memberSophie Vandebroek V. Feb 1, 2024 to now53
- Board memberMichelle McMurry-Heath Jul 25, 2022 to now54
- Board memberPrahlad R. Singh Jan 31, 2020 to now55
- Board memberPascale Witz Oct 30, 2017 to now56
- Board memberFrank Witney Jul 27, 2016 to now57
- Board memberSamuel R. Chapin Oct 17, 2016 to now58
- Board memberSylvie Gregoire Feb 10, 2015 to May 17, 202359
- Board memberPeter Barrett Feb 6, 2012 to now60
- Board memberPatrick J. Sullivan Feb 26, 2008 to May 1, 201961
- Board memberRobert F. Friel Feb 2, 2006 to Oct 2, 201844
- Board memberAlexis P. Michas Feb 11, 2004 to now62
- Board memberG. Robert Tod Apr 29, 2004 to Feb 15, 201263
- Board memberGabriel Schmergel Apr 29, 2004 to Feb 17, 201264
- Board memberKenton J. Sicchitano Apr 29, 2004 to Aug 25, 201665
- Board memberNicholas A. Lopardo Apr 29, 2004 to Feb 7, 201966
- Board memberVicki L. Sato Apr 29, 2004 to Feb 10, 201767
- Board memberTamara J. Erickson Aug 28, 2003 to Feb 15, 200768
- General counselJoel S. Goldberg Jul 21, 2008 to Jan 31, 201269
- General counselKatherine A. Ohara May 3, 2005 to Feb 1, 200770
- General counselTerrance L. Carlson Oct 24, 2003 to Jan 29, 200471
Subsidiaries and ownership
Subsidiaries
- BioLegend
- EUROIMMUN Medizinische Labordiagnostika AG (Germany)
From Wikidata.1
Former names
Controversies and legal
Regulatory Approvals
In June 2023, Revvity's Euroimmun business received CE-IVDR certification for the UNIQO 160, an automated indirect immunofluorescence testing (IIFT) system that integrates sample preparation, incubation, slide washing and mounting, image acquisition, and image analysis.
In November 2023, Revvity's EONIS Q system received CE-IVD certification for molecular newborn screening of spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID).
In January 2025, Revvity’s Euroimmun received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its automated chemiluminescence-based immunoassay (ChLIA) free testosterone test, providing direct quantitative measurement of free testosterone levels used to aid the diagnosis of androgen disorders. In May 2026, Revvity’s subsidiary, Immunodiagnostic Systems (IDS), received clearance from the FDA for a total testosterone ChLIA test, complementing the company’s existing FDA-cleared ChLIA tests for free testosterone and sex hormone-binding globulin (SHBG). Together, these clearances enable first- and second-line diagnostic testing capabilities for suspected hypogonadism in men on a single automated platform.
In March 2025, Revvity’s Euroimmun received CE marking for the Anti-Measles Virus ELISA 2.0 (IgG), a measles antibody detection assay to support the diagnosis of a measles virus infection or to determine the immune status against measles virus.
In April 2025, Revvity received FDA approval for the Auto-Pure 2400 liquid handling platform in combination with the T-SPOT.TB test for automated latent tuberculosis detection.
In May 2025, Revvity’s Euroimmun launched the IDS i20 analytical random access platform, enabling full automation of chemiluminescence immunoassays (ChLIA). The CE-marked and FDA-listed device allows laboratories to consolidate multiple specialty tests on a single instrument, processing specialty assays in endocrinology, allergy, autoimmune and infectious diseases, Alzheimer’s disease, and therapeutic drug monitoring.
From Wikipedia’s article on Revvity, shared under CC BY-SA 4.0.6
Timeline
Recent filings
- Oct 7, 2026SCHEDULE 13G/A
- Oct 2, 20264
- Oct 1, 2026144
- Sep 23, 20264
- Sep 21, 2026144
- Sep 18, 20264
- Sep 16, 2026144
- Sep 8, 2026SCHEDULE 13G/A
- Aug 25, 20264
- Aug 18, 20264
- Aug 17, 20264
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G/A
- Aug 11, 202610-Q
- Aug 4, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websiterevvity.com1
- X (Twitter)x.com/RevvityInc1
- Facebookwww.facebook.com/RevvityInc1
- Instagramwww.instagram.com/revvity1
- YouTubewww.youtube.com/channel/UCUqLrqOpUUwhz3UaLn78tVQ1
- LinkedInwww.linkedin.com/company/https://www.linkedin.com/company/revvity/?viewAsMember=true1
- WikipediaRevvity
- WikidataQ120467527
- SEC EDGARCIK 31791
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataRevvity Inc. on Wikidata
- 2SEC EDGARRevvity Inc. filings on SEC EDGAR
- 3WikipediaRevvity Inc. on Wikipedia
- 4Wikimedia CommonsRevvity Inc. logo by Revvity, Inc., Public domain
- 5SEC EDGARRevvity Inc. filings on SEC EDGAR
- 6
- 7SEC EDGARRevvity Inc. 10-K for fiscal 2025
- 8SEC EDGARRevvity Inc. 10-K for fiscal 2019
- 9SEC EDGARRevvity Inc. 10-K for fiscal 2021
- 10SEC EDGARRevvity Inc. 10-K for fiscal 2022
- 11SEC EDGARRevvity Inc. 10-K for fiscal 2019
- 12SEC EDGARRevvity Inc. 10-Q for fiscal 2026
- 13SEC EDGARRevvity Inc. 10-Q for fiscal 2026
- 14SEC EDGARRevvity Inc. 10-K for fiscal 2023
- 15
- 16
- 17SEC EDGARRobert F. Friel, Chair
- 18SEC EDGARPrahlad R. Singh, President
- 19SEC EDGARJames Corbett, President
- 20SEC EDGARRobert F. Friel, President
- 21SEC EDGARGregory L. Summe, President
- 22
- 23
- 24
- 25
- 26SEC EDGARAnita Gonzales, Officer
- 27SEC EDGARMaxwell Krakowiak, Officer
- 28SEC EDGARMiriame Victor, Officer
- 29SEC EDGARTajinder Vohra, Officer
- 30SEC EDGARJames M. Mock, Officer
- 31SEC EDGARDaniel R. Tereau, Officer
- 32SEC EDGARDeborah A. Butters, Officer
- 33SEC EDGARPrahlad R. Singh, Officer
- 34SEC EDGARFrank Anders Wilson, Officer
- 35SEC EDGARJonathan Divincenzo, Officer
- 36SEC EDGARE. Kevin Hrusovsky, Officer
- 37SEC EDGARMaurice H. Tenney, Officer
- 38SEC EDGARJames Corbett, Officer
- 39SEC EDGARJoel S. Goldberg, Officer
- 40
- 41
- 42SEC EDGARDaniel R. Marshak, VP AND CSO
- 43
- 44SEC EDGARRobert F. Friel, Vice chair
- 45
- 46SEC EDGARJohn A. Roush, Vice President
- 47
- 48
- 49SEC EDGARPeter B. Coggins, Sr. Vice President
- 50
- 51
- 52SEC EDGARMichael A. Klobuchar, Board member
- 53SEC EDGARSophie Vandebroek V., Board member
- 54SEC EDGARMichelle McMurry-Heath, Board member
- 55SEC EDGARPrahlad R. Singh, Board member
- 56SEC EDGARPascale Witz, Board member
- 57SEC EDGARFrank Witney, Board member
- 58SEC EDGARSamuel R. Chapin, Board member
- 59SEC EDGARSylvie Gregoire, Board member
- 60SEC EDGARPeter Barrett, Board member
- 61SEC EDGARPatrick J. Sullivan, Board member
- 62SEC EDGARAlexis P. Michas, Board member
- 63SEC EDGARG. Robert Tod, Board member
- 64SEC EDGARGabriel Schmergel, Board member
- 65SEC EDGARKenton J. Sicchitano, Board member
- 66SEC EDGARNicholas A. Lopardo, Board member
- 67SEC EDGARVicki L. Sato, Board member
- 68SEC EDGARTamara J. Erickson, Board member
- 69SEC EDGARJoel S. Goldberg, General counsel
- 70SEC EDGARKatherine A. Ohara, General counsel
- 71SEC EDGARTerrance L. Carlson, General counsel